Vicapsys Life Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
November 12, 2021 at 11:31 am
Share
Vicapsys Life Sciences, Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported net loss was USD 0.111181 million compared to USD 0.089221 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.01 a year ago.
For the nine months, net loss was USD 0.133013 million compared to USD 0.685295 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.04 a year ago.
Vicapsys Life Sciences, Inc. develops and commercializes, on a worldwide basis, various intellectual property rights relating to a series of encapsulated products that incorporate proprietary derivatives of the chemokine CXCL12 for creating a zone of immunoprotection around cells, tissues, organs and devices for therapeutic purposes. VICAPSYN is the Companyâs product line that is applied to transplantation therapies and related stem-cell applications in the transplantation field. The lead product candidate embodiment in transplantation therapy to treat Type 1 Diabetes (T1D) is an encapsulated human islet cell cluster that is intended to restore normal glucose control when implanted into the peritoneal cavity of a patient. It also develops another product candidate line based on CXCL12 with the trade name of VYBRIN. The clinical applications of VYBRIN are being explored in several areas, including prevention of post-surgical adhesions in abdominal surgery and others.
VICAPSYS LIFE SCIENCES, INC. 
